Concepts and targets in triple-negative breast cancer: recent results and clinical implications
Triple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) receptor. No targeted therapies are available for the treatment of...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-09-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834016657071 |
id |
doaj-c38c1acdbc4f4c8a8a18a60ed40d8efc |
---|---|
record_format |
Article |
spelling |
doaj-c38c1acdbc4f4c8a8a18a60ed40d8efc2020-11-25T02:53:44ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83401758-83592016-09-01810.1177/1758834016657071Concepts and targets in triple-negative breast cancer: recent results and clinical implicationsPoornima SahaRita NandaTriple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) receptor. No targeted therapies are available for the treatment of TNBC, and chemotherapy remains the standard of care. Gene expression profiling has identified six distinct molecular subtypes of TNBC. The identification of novel targets, coupled with the development of therapies for different subsets of TNBC, holds great promise for the future treatment of this aggressive form of breast cancer. This review focuses on novel therapies in development for the treatment of TNBC.https://doi.org/10.1177/1758834016657071 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Poornima Saha Rita Nanda |
spellingShingle |
Poornima Saha Rita Nanda Concepts and targets in triple-negative breast cancer: recent results and clinical implications Therapeutic Advances in Medical Oncology |
author_facet |
Poornima Saha Rita Nanda |
author_sort |
Poornima Saha |
title |
Concepts and targets in triple-negative breast cancer: recent results and clinical implications |
title_short |
Concepts and targets in triple-negative breast cancer: recent results and clinical implications |
title_full |
Concepts and targets in triple-negative breast cancer: recent results and clinical implications |
title_fullStr |
Concepts and targets in triple-negative breast cancer: recent results and clinical implications |
title_full_unstemmed |
Concepts and targets in triple-negative breast cancer: recent results and clinical implications |
title_sort |
concepts and targets in triple-negative breast cancer: recent results and clinical implications |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Medical Oncology |
issn |
1758-8340 1758-8359 |
publishDate |
2016-09-01 |
description |
Triple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack of expression of the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) receptor. No targeted therapies are available for the treatment of TNBC, and chemotherapy remains the standard of care. Gene expression profiling has identified six distinct molecular subtypes of TNBC. The identification of novel targets, coupled with the development of therapies for different subsets of TNBC, holds great promise for the future treatment of this aggressive form of breast cancer. This review focuses on novel therapies in development for the treatment of TNBC. |
url |
https://doi.org/10.1177/1758834016657071 |
work_keys_str_mv |
AT poornimasaha conceptsandtargetsintriplenegativebreastcancerrecentresultsandclinicalimplications AT ritananda conceptsandtargetsintriplenegativebreastcancerrecentresultsandclinicalimplications |
_version_ |
1724724771235561472 |